Head to Head Contrast: BioNTech (NASDAQ:BNTX) versus Cyclo Therapeutics (NASDAQ:CYTH)

BioNTech (NASDAQ:BNTX) and Cyclo Therapeutics (NASDAQ:CYTH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for BioNTech and Cyclo Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0	3	14	1	2.89
Cyclo Therapeutics	0	2	1	0	2.33

BioNTech presently has a consensus target price of $143.44, suggesting a potential upside of 62.90%. Cyclo Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 31.83%. Given BioNTech’s stronger consensus rating and higher probable upside, equities research analysts clearly believe BioNTech is more favorable than Cyclo Therapeutics.

Volatility and Risk

BioNTech has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.57, indicating that its share price is 157% less volatile than the S&P 500.

Profitability

This table compares BioNTech and Cyclo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNTech	-15.16%	-2.35%	-2.05%
Cyclo Therapeutics	-2,847.19%	N/A	-307.16%

Earnings and Valuation

This table compares BioNTech and Cyclo Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.75 billion	7.68	$1.01 billion	($3.00)	-29.35
Cyclo Therapeutics	$870,725.00	27.24	-$20.06 million	($0.90)	-0.80

BioNTech has higher revenue and earnings than Cyclo Therapeutics. BioNTech is trading at a lower price-to-earnings ratio than Cyclo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

15.5% of BioNTech shares are held by institutional investors. Comparatively, 68.6% of Cyclo Therapeutics shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BioNTech beats Cyclo Therapeutics on 9 of the 15 factors compared between the two stocks.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.